Articles

Prostate Cancer

Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study

By: Giuseppe Di Lorenzoa lowast , William D. Figgb, Sophie D. Fossac, Vincenzo Mironed, Riccardo Autorinoe, Nicola Longod, Ciro Imbimbod, Sisto Perdonàf, Antonio Giordanoa, Mario Giulianoa, Roberto Labiancag and Sabino De Placidoa

European Urology, Volume 54 Issue 1, November 2008, Pages 1089-1096

Published online: 01 November 2008

Keywords: Bevacizumab, Chemotherapy, Docetaxel, Hormone-refractory prostate cancer

Abstract Full Text Full Text PDF (330 KB)

Abstract

Objective

Although the taxanes represent the most active agents for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC), most patients eventually progress while receiving taxane-based treatments. No agents are approved for second-line therapy in HRPC, but common standard practice for the oncologists is to treat patients also after docetaxel failure.

Methods

Twenty highly pretreated patients with HRPC received bevacizumab (10mg/kg) and docetaxel (60mg/m2) every 3 wk. All patients had bone metastases and eight had measurable lesions.

Results

Eleven patients (55%) had major prostate-specific antigen (PSA) responses, and 3 (37.5%) had objective responses. Seven major PSA responses were recorded in the same patients who had reported a >50% PSA decrease after first-line docetaxel. However, four major PSA responses were observed in patients previously nonresponsive to docetaxel alone. The treatment was well tolerated.

Conclusions

Our results show that the combination of bevacizumab and docetaxel is active and well tolerated. Continued investigation of bevacizumab with cytotoxic chemotherapy is warranted in HRPC.

Take Home Message

The combination of bevacizumab and docetaxel is active and well tolerated in docetaxel-pretreated hormone-refractory prostate cancer patients. This regimen needs to be further evaluated and compared with docetaxel alone in this setting.

Keywords: Bevacizumab, Chemotherapy, Docetaxel, Hormone-refractory prostate cancer.

Footnotes

a Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy

b Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

c Rikshospital, Cancer Clinic, University of Oslo, Norway

d Clinica Urologica, Università degli Studi Federico II, Napoli, Italy

e Clinica Urologica, Seconda Università degli Studi, Naples, Italy

f U.O. Urologia, Istituto Nazionale Tumori, Fondazione “G. Pascale” IRCSS Napoli, Italy

g Oncology Section, Ospedali Riuniti, Bergamo, Italy

lowast Corresponding author. Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy. Tel. +39 081 7463660; Fax: +39 081 8997370.

Place a comment

Your comment *

max length: 5000